vs
CATALYST PHARMACEUTICALS, INC.（CPRX）とCSW INDUSTRIALS, INC.（CSW）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSW INDUSTRIALS, INC.の直近四半期売上が大きい（$233.0M vs $152.6M、CATALYST PHARMACEUTICALS, INC.の約1.5倍）。CATALYST PHARMACEUTICALS, INC.の純利益率が高く（34.5% vs 4.4%、差は30.1%）。CSW INDUSTRIALS, INC.の前年同期比売上増加率が高い（20.3% vs 7.6%）。CATALYST PHARMACEUTICALS, INC.の直近四半期フリーキャッシュフローが多い（$44.9M vs $22.7M）。過去8四半期でCATALYST PHARMACEUTICALS, INC.の売上複合成長率が高い（24.5% vs 5.1%）
Catalyst Pharmaceuticalsは米国フロリダ州コーラルゲーブルズに本拠を置くバイオ医薬品企業で、希少疾患向け治療薬の開発を事業の核心としています。主力品にランバート・イートン筋無力症候群（LEMS）治療薬のアミファンプリジンリン酸塩（商品名Firdapse）があり、2018年11月のFDA承認により、既存の成人に加え6歳以上の小児LEMS患者への投与も認められました。
CPRX vs CSW — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $152.6M | $233.0M |
| 純利益 | $52.7M | $10.3M |
| 粗利率 | 82.9% | 39.7% |
| 営業利益率 | 40.5% | 7.4% |
| 純利益率 | 34.5% | 4.4% |
| 売上前年比 | 7.6% | 20.3% |
| 純利益前年比 | -5.8% | -61.9% |
| EPS（希薄化後） | $0.40 | $0.62 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $152.6M | $233.0M | ||
| Q3 25 | $148.4M | $277.0M | ||
| Q2 25 | $146.6M | $263.6M | ||
| Q1 25 | $141.4M | $230.5M | ||
| Q4 24 | $141.8M | $193.6M | ||
| Q3 24 | $128.7M | $227.9M | ||
| Q2 24 | $122.7M | $226.2M | ||
| Q1 24 | $98.5M | $210.9M |
| Q4 25 | $52.7M | $10.3M | ||
| Q3 25 | $52.8M | $40.7M | ||
| Q2 25 | $52.1M | $40.9M | ||
| Q1 25 | $56.7M | $35.1M | ||
| Q4 24 | $55.9M | $26.9M | ||
| Q3 24 | $43.9M | $36.1M | ||
| Q2 24 | $40.8M | $38.6M | ||
| Q1 24 | $23.3M | $31.8M |
| Q4 25 | 82.9% | 39.7% | ||
| Q3 25 | 84.7% | 43.0% | ||
| Q2 25 | 85.9% | 43.8% | ||
| Q1 25 | 87.3% | 44.2% | ||
| Q4 24 | 84.7% | 41.4% | ||
| Q3 24 | 85.0% | 45.6% | ||
| Q2 24 | 87.4% | 47.5% | ||
| Q1 24 | 87.3% | 44.4% |
| Q4 25 | 40.5% | 7.4% | ||
| Q3 25 | 44.7% | 20.5% | ||
| Q2 25 | 45.2% | 20.8% | ||
| Q1 25 | 44.8% | 19.5% | ||
| Q4 24 | 44.3% | 15.3% | ||
| Q3 24 | 39.6% | 22.6% | ||
| Q2 24 | 44.2% | 24.3% | ||
| Q1 24 | 27.5% | 21.0% |
| Q4 25 | 34.5% | 4.4% | ||
| Q3 25 | 35.6% | 14.7% | ||
| Q2 25 | 35.6% | 15.5% | ||
| Q1 25 | 40.1% | 15.2% | ||
| Q4 24 | 39.4% | 13.9% | ||
| Q3 24 | 34.1% | 15.8% | ||
| Q2 24 | 33.2% | 17.1% | ||
| Q1 24 | 23.6% | 15.1% |
| Q4 25 | $0.40 | $0.62 | ||
| Q3 25 | $0.42 | $2.41 | ||
| Q2 25 | $0.41 | $2.43 | ||
| Q1 25 | $0.45 | $2.05 | ||
| Q4 24 | $0.44 | $1.60 | ||
| Q3 24 | $0.35 | $2.26 | ||
| Q2 24 | $0.33 | $2.47 | ||
| Q1 24 | $0.19 | $2.03 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $709.2M | $40.2M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $954.3M | $1.1B |
| 総資産 | $1.1B | $2.3B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $709.2M | $40.2M | ||
| Q3 25 | $689.9M | $31.5M | ||
| Q2 25 | $652.8M | $38.0M | ||
| Q1 25 | $580.7M | $225.8M | ||
| Q4 24 | $517.6M | $213.8M | ||
| Q3 24 | $442.3M | $273.2M | ||
| Q2 24 | $375.7M | $18.9M | ||
| Q1 24 | $310.4M | $22.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $800.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $166.0M |
| Q4 25 | $954.3M | $1.1B | ||
| Q3 25 | $920.2M | $1.1B | ||
| Q2 25 | $856.0M | $1.1B | ||
| Q1 25 | $794.3M | $1.1B | ||
| Q4 24 | $727.6M | $1.0B | ||
| Q3 24 | $660.9M | $1.0B | ||
| Q2 24 | $608.7M | $650.2M | ||
| Q1 24 | $561.4M | $615.7M |
| Q4 25 | $1.1B | $2.3B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $971.9M | $1.5B | ||
| Q1 25 | $908.9M | $1.4B | ||
| Q4 24 | $851.4M | $1.4B | ||
| Q3 24 | $772.0M | $1.4B | ||
| Q2 24 | $706.4M | $1.1B | ||
| Q1 24 | $646.7M | $1.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.27× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $44.9M | $28.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $44.9M | $22.7M |
| FCFマージンFCF / 売上 | 29.4% | 9.8% |
| 設備投資強度設備投資 / 売上 | 0.0% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 0.85× | 2.81× |
| 直近12ヶ月FCF直近4四半期 | — | $162.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $44.9M | $28.9M | ||
| Q3 25 | $32.4M | $61.8M | ||
| Q2 25 | $71.3M | $60.6M | ||
| Q1 25 | $60.0M | $27.3M | ||
| Q4 24 | $70.9M | $11.6M | ||
| Q3 24 | $72.9M | $66.8M | ||
| Q2 24 | $64.1M | $62.7M | ||
| Q1 24 | $31.9M | $22.4M |
| Q4 25 | $44.9M | $22.7M | ||
| Q3 25 | — | $58.7M | ||
| Q2 25 | $71.3M | $57.7M | ||
| Q1 25 | — | $22.8M | ||
| Q4 24 | $70.8M | $8.5M | ||
| Q3 24 | $72.6M | $61.3M | ||
| Q2 24 | $64.1M | $59.6M | ||
| Q1 24 | $31.7M | $17.5M |
| Q4 25 | 29.4% | 9.8% | ||
| Q3 25 | — | 21.2% | ||
| Q2 25 | 48.6% | 21.9% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | 49.9% | 4.4% | ||
| Q3 24 | 56.4% | 26.9% | ||
| Q2 24 | 52.3% | 26.3% | ||
| Q1 24 | 32.2% | 8.3% |
| Q4 25 | 0.0% | 2.6% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 2.0% | ||
| Q4 24 | 0.1% | 1.6% | ||
| Q3 24 | 0.2% | 2.4% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.2% | 2.3% |
| Q4 25 | 0.85× | 2.81× | ||
| Q3 25 | 0.61× | 1.52× | ||
| Q2 25 | 1.37× | 1.48× | ||
| Q1 25 | 1.06× | 0.78× | ||
| Q4 24 | 1.27× | 0.43× | ||
| Q3 24 | 1.66× | 1.85× | ||
| Q2 24 | 1.57× | 1.62× | ||
| Q1 24 | 1.37× | 0.71× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
